inclusion criteria: 1. subject must sign written informed consent to participate in the trial. 2. subject is able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of the study by passing a quiz (assessment of understanding). subjects must score at least 80% correct on a multiple-choice quiz. if they do not score 80% on the initial quiz, the protocol information will be reviewed with them, and they will have the opportunity to retest. 3. in the opinion of the investigator, the subject can and will comply with the requirements of the protocol. 4. subjects are available to attend all study visits and are reachable by phone throughout the entire study period from day -1 until 24 weeks following last vaccination (end of study). 5. subject is a male or non-pregnant and non-lactating female age ≥ 18 and ≤ 55 years and in good health at time of abncov2 administration. 6. subject agrees to their general practitioner (gp) being informed about participation in the study and agrees to sign a form to request the release by their gp, and medical specialist when necessary, of any relevant medical information concerning possible contra-indications for participation in the study to the investigator(s). 7. the subject agrees to refrain from blood donation to sanquin or for other purposes throughout the study period according to current sanquin guidelines. 8. female subjects of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. all other female subjects must agree to use continuous adequate contraception2 for the duration of the study. female subjects must have a negative pregnancy test at the inclusion visit.

inclusion criteria: 1. subject must sign written informed consent to participate in the trial. 2. subject is able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of the study by passing a quiz (assessment of understanding). subjects must score at least 80% correct on a multiple-choice quiz. if they do not score 80% on the initial quiz, the protocol information will be reviewed with them, and they will have the opportunity to retest. 3. in the opinion of the investigator, the subject can and will comply with the requirements of the protocol. 4. subjects are available to attend all study visits and are reachable by phone throughout the entire study period from day -1 until 24 weeks following last vaccination (end of study). 5. subject is a male or non-pregnant and non-lactating female age ≥ 18 and ≤ 55 years and in good health at time of abncov2 administration. 6. subject agrees to their general practitioner (gp) being informed about participation in the study and agrees to sign a form to request the release by their gp, and medical specialist when necessary, of any relevant medical information concerning possible contra-indications for participation in the study to the investigator(s). 7. the subject agrees to refrain from blood donation to sanquin or for other purposes throughout the study period according to current sanquin guidelines. 8. female subjects of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. all other female subjects must agree to use continuous adequate contraception2 for the duration of the study. female subjects must have a negative pregnancy test at the inclusion visit.

inclusion criteria: subject must sign written informed consent to participate in the trial. subject is able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of the study by passing a quiz (assessment of understanding). subjects must score at least 80% correct on a multiple-choice quiz. if they do not score 80% on the initial quiz, the protocol information will be reviewed with them, and they will have the opportunity to retest. in the opinion of the investigator, the subject can and will comply with the requirements of the protocol. subjects are available to attend all study visits and are reachable by phone throughout the entire study period from day -1 until 24 weeks following last vaccination (end of study). subject is a male or non-pregnant and non-lactating female age ≥ 18 and ≤ 55 years and in good health at time of abncov2 administration. subject agrees to their general practitioner (gp) being informed about participation in the study and agrees to sign a form to request the release by their gp, and medical specialist when necessary, of any relevant medical information concerning possible contra-indications for participation in the study to the investigator(s). the subject agrees to refrain from blood donation to sanquin or for other purposes throughout the study period according to current sanquin guidelines. female subjects of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. all other female subjects must agree to use continuous adequate contraception2 for the duration of the study. female subjects must have a negative pregnancy test at the inclusion visit.

inclusion criteria: subject must sign written informed consent to participate in the trial. subject is able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of the study by passing a quiz (assessment of understanding). subjects must score at least 80% correct on a multiple-choice quiz. if they do not score 80% on the initial quiz, the protocol information will be reviewed with them, and they will have the opportunity to retest. in the opinion of the investigator, the subject can and will comply with the requirements of the protocol. subjects are available to attend all study visits and are reachable by phone throughout the entire study period from day -1 until 24 weeks following last vaccination (end of study). subject is a male or non-pregnant and non-lactating female age ≥ 18 and ≤ 55 years and in good health at time of abncov2 administration. subject agrees to their general practitioner (gp) being informed about participation in the study and agrees to sign a form to request the release by their gp, and medical specialist when necessary, of any relevant medical information concerning possible contra-indications for participation in the study to the investigator(s). the subject agrees to refrain from blood donation to sanquin or for other purposes throughout the study period according to current sanquin guidelines. female subjects of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. all other female subjects must agree to use continuous adequate contraception2 for the duration of the study. female subjects must have a negative pregnancy test at the inclusion visit.

inclusion criteria: 1. subject must sign written informed consent to participate in the trial. 2. subject is able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of the study by passing a quiz (assessment of understanding). subjects must score at least 80% correct on a multiple-choice quiz. if they do not score 80% on the initial quiz, the protocol information will be reviewed with them, and they will have the opportunity to retest. 3. in the opinion of the investigator, the subject can and will comply with the requirements of the protocol. 4. subjects are available to attend all study visits and are reachable by phone throughout the entire study period from day -1 until 24 weeks following last vaccination (end of study). 5. subject is a male or non-pregnant and non-lactating female age ≥ 18 and ≤ 55 years and in good health at time of abncov2 administration. 6. subject agrees to their general practitioner (gp) being informed about participation in the study and agrees to sign a form to request the release by their gp, and medical specialist when necessary, of any relevant medical information concerning possible contra-indications for participation in the study to the investigator(s). 7. the subject agrees to refrain from blood donation to sanquin or for other purposes throughout the study period according to current sanquin guidelines. 8. female subjects of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. all other female subjects must agree to use continuous adequate contraception2 for the duration of the study. female subjects must have a negative pregnancy test at the inclusion visit.

inclusion criteria: 1. subject must sign written informed consent to participate in the trial. 2. subject is able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of the study by passing a quiz (assessment of understanding). subjects must score at least 80% correct on a multiple-choice quiz. if they do not score 80% on the initial quiz, the protocol information will be reviewed with them, and they will have the opportunity to retest. 3. in the opinion of the investigator, the subject can and will comply with the requirements of the protocol. 4. subjects are available to attend all study visits and are reachable by phone throughout the entire study period from day -1 until 24 weeks following last vaccination (end of study). 5. subject is a male or non-pregnant and non-lactating female age ≥ 18 and ≤ 55 years and in good health at time of abncov2 administration. 6. subject agrees to their general practitioner (gp) being informed about participation in the study and agrees to sign a form to request the release by their gp, and medical specialist when necessary, of any relevant medical information concerning possible contra-indications for participation in the study to the investigator(s). 7. the subject agrees to refrain from blood donation to sanquin or for other purposes throughout the study period according to current sanquin guidelines. 8. female subjects of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. all other female subjects must agree to use continuous adequate contraception2 for the duration of the study. female subjects must have a negative pregnancy test at the inclusion visit.